Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?

Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?

To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A [<i>n</i> = 40], B [<i>n</i> = 60], and C [<i>n</i>...

Full description

Bibliographic Details
Main Authors: Tae Hyun Kim, Joong-Won Park, Bo Hyun Kim, Hyunjung Kim, Sung Ho Moon, Sang Soo Kim, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Dae Yong Kim, Chang-Min Kim
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
hepatocellular carcinoma
proton beam therapy
overall survival
Online Access:https://www.mdpi.com/2072-6694/11/2/230

Internet

https://www.mdpi.com/2072-6694/11/2/230

Similar Items